At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 303 enrolled
Drug / intervention
biphasic insulin aspart +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-labelled, Randomised, Parallel Group, Multicentre, Multinational Efficacy and Safety Comparison of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30/70 as Meal Related Insulin in a Twice Daily Regimen in Type 1 and Type 2 Diabetic Subjects
In Brief
A Phase 3 clinical trial evaluating biphasic insulin aspart and biphasic human insulin for Diabetes and 2 related conditions. Completed, enrolled 303 participants across 37 sites in 5 countries.
Detailed Summary
This trial is conducted in Europe. The aim of this trial is to evaluate the efficacy and safety of biphasic insulin aspart 30 in subjects with type 1 or type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustria, Germany, Ireland, Switzerland, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 1998
Primary CompletionSep 1998
First PostedNov 2011
TodayJul 2026
First PostedNov 8, 2011
Enrollment StartApr 1, 1998
Primary CompletionSep 1, 1998
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 14.7 years ago
Interventions
biphasic insulin aspartdrug
Injected subcutaneously (under the skin) twice daily
biphasic human insulindrug
Injected subcutaneously (under the skin) twice daily